The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Validation of rano criteria: Contribution of T2/FLAIR assessment in patients with recurrent glioblastoma treated with bevacizumab.
Raymond Yi-kun Huang
No relevant relationships to disclose
Rifaquat Rahman
No relevant relationships to disclose
Whitney B. Pope
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Benjamin M. Ellingson
Consultant or Advisory Role - MedQIA (U); Roche/Genentech (U)
S. Keith Anderson
No relevant relationships to disclose
Sara J Felten
No relevant relationships to disclose
Karla V. Ballman
No relevant relationships to disclose
Wenting Wu
No relevant relationships to disclose
Lakshmi Nayak
No relevant relationships to disclose
Eudocia Quant Lee
Consultant or Advisory Role - Genentech
Lauren E. Abrey
Employment or Leadership Position - Roche
Evanthia Galanis
No relevant relationships to disclose
David A. Reardon
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Timothy Francis Cloughesy
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Patrick Y. Wen
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Roche/Genentech